All In Biotech

Drug Trial Radar · NCT00224146

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder

Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)

Last checked: Nov 20, 2026Latest source record: Nov 30, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,878 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,878

Actual

Start

May 2004

Primary completion

May 2005

Study completion May 2005

Sponsor

Lead sponsor
Watson PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)

Conditions

  • Overactive Bladder
  • Urinary Incontinence
  • Quality of Life

Interventions

  • oxybutynin transdermal delivery system (Oxytrol(r))Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in health-related quality of life

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Mobile, Alabama

  • Site not named

    Tucson, Arizona

  • Site not named

    Torrance, California

  • Site not named

    Rocky Hill, Connecticut

  • Site not named

    Valdosta, Georgia

  • Site not named

    Gretna, Louisiana

  • Site not named

    Bloomfield Hills, Michigan

  • Site not named

    Poughkeepsie, New York

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Tomball, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.